https://www.selleckchem.com/pr....oducts/ziritaxestat.
419-0.555; HR of HER2 subtype, 0.542, 95% CI 0.484-0.608). Brain metastasis impacts overall survival (OS) ( 0.001) fundamentally, and visceral metastases also significantly decreased OS ( 0.001). Bone metastasis patients present a more favorable oncological survival consequence than other metastases, and the TNBC subtype with bone metastasis showed the poorest tumor outcome compared with the other three molecular subtypes. Bone metastasis patients present a more favorable oncological survival consequence than other metast
Like
Comment
Share
